View Financial HealthIIOT-OXYS 配当と自社株買い配当金 基準チェック /06IIOT-OXYS配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 01IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2026, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 11/14/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 08/14/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 16IIOT-OXYS, Inc. announced delayed 10-Q filingOn 05/15/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 22IIOT-OXYS, Inc. announced that it expects to receive $0.21 million in funding from GHS Investments, LLCIIOT-OXYS, Inc. entered into a Securities Purchase Agreement with returning investor GHS Investments, LLC in the amount of up to $210,000 on MArch 21, 2025. The SPA provides for GHS’s purchase, from time to time, of up to 210 shares of the Company’s newly-designated Series D Convertible Preferred Stock (the “ Preferred Stock ”). The initial closing under the SPA consisted of 60 shares of Preferred Stock, stated value $1,200 per share, issued to GHS for an initial purchase price of $60,000, or $1,000 per share. At GHS and the Company’s option, and subject to the terms of the SPA and the Certificate of Designation for the Preferred Stock (the “ COD ”), additional closings in the aggregate amount of up to 150 shares of Preferred Stock for a total aggregate purchase price of up to $150,000 may take place.お知らせ • Nov 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 11/14/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 08/14/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18IIOT-OXYS, Inc. announced delayed 10-Q filingOn 05/16/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 04/01/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jun 16IIOT-OXYS, Inc. Appoints William D'Agostino to its Advisory BoardIIOT-OXYS, Inc. announced the appointment of William D'Agostino to its Advisory Board as a Technical Sales Consultant for his expertise in Biotechnology and Pharmaceutical Continuous Manufacturing Processes.お知らせ • May 16IIOT-OXYS, Inc. announced delayed 10-Q filingOn 05/15/2023, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 01IIOT-OXYS, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 , First Quarter and Full Year of 2023IIOT-OXYS, Inc. provided revenue guidance for the fourth quarter and full year ended December 31, 2022, first quarter and full year of 2023. As predicted, the fourth quarter revenue exceeded that in the third quarter. Overall, 2022 annual revenue exceeded that of 2020 and 2021 combined.This first quarter of 2023 is already on track to exceed the fourth quarter revenue in 2022. Overall, The company expects 2023 revenue to exceed that in 2022.お知らせ • Dec 06IIOT-OXYS, Inc. announced that it has received $0.061 million in fundingOn December 5, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. J.H. Darbie & Co., Inc. acted as a finder in the transaction. The company has paid $1,220 as finder fee in the transaction.お知らせ • Nov 25IIOT-OXYS, Inc. Provides Revenue Guidance for the Second Half and Full Year 2022IIOT-OXYS, Inc. provided revenue guidance for the second half and full year 2022. The company expected revenue for the second half of 2022 will exceed that generated in the first half of 2022.In total, the company expected that total revenue for 2022 will be approaching 2019 levels.お知らせ • Jul 13IIOT-OXYS, Inc. announced that it has received $0.027273 million in fundingOn July 12, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. The company has paid $546 to the finder J.H. Darbie & Co.お知らせ • Jun 24IIOT-OXYS, Inc. announced that it has received $0.030144 million in fundingOn June 23, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. The company has paid $603 to the finder J.H. Darbie & Co.お知らせ • Jun 09+ 2 more updatesIIOT-OXYS, Inc. Announces CFO ChangesIIOT-OXYS, Inc. announced that on June 2, 2022, Clifford L. Emmons resigned as Interim Chief Financial Officer and, on the same date, Karen McNemar, age 53, was appointed as the Interim Chief Financial Officer (Principal Financial and Accounting Officer) of the Company. Except as mentioned herein, there are no other arrangements or understandings between Ms. McNemar and any other persons pursuant to which Ms. McNemar was selected in the officer position above. There are no family relationships between Ms. McNemar and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer. Ms. McNemar has served as Chief Operating Officer since September 20, 2018. From 1998 until August 2017, Ms. McNemar served in many capacities for Medtronic which included as a Senior Director of R&D Operations. Ms. McNemar is a collaborative strategic global business leader with extensive experience in New Product Development and Operations, building strong and effective diverse teams across organizations at all levels. Ms. McNemar is also a trusted advisor, recognized for successful process and program management, with a focus on leading complex initiatives and analyzing data and processes to identify solutions to increase organizational productivity and performance. Ms. McNemar received her Bachelor of Science in Industrial Engineering and Operations Research.お知らせ • May 24IIOT-OXYS, Inc. announced that it has received $0.043096 million in fundingOn May 23, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. The company has paid $4,310 to the finder J.H. Darbie & Co.お知らせ • Apr 01IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2022, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 26IIOT-OXYS, Inc. announced that it has received $0.051 million in fundingOn February 24, 2022, IIOT-OXYS, Inc. closed the transaction. The company has received funding from one investor.お知らせ • Apr 02IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2021, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 18IIOT-OXYS, Inc. Appoints Chandran Seshagiri as Company's Advisory Board ChairmanIIOT-OXYS, Inc. announced the appointment of Chandran Seshagiri as the company's Advisory Board Chairman. Chandran is uniquely qualified to lead company Advisory Board, as he has made significant contributions to company past successful projects and continues to lead company algorithm development efforts on current and future projects. His passion for transforming complex signals into actionable information began with his work at the Harvard-MIT Division of Health Sciences and Technology, where he completed his Ph.D. Chandran's work analyzing physiological time series signals to enable personalized delivery of anesthesia as well as neurostimulation therapy has translated well to the time series data and predictive analyses required for Smart Manufacturing and Structural Health Monitoring applications for IIOT-OXYS, Inc.'s customers.お知らせ • Sep 28IIOT-OXYS, Inc. (OTCPK:ITOX) entered into a letter of intent to acquire Infinite Automation Systems, Inc.IIOT-OXYS, Inc. (OTCPK:ITOX) entered into a letter of intent to acquire Infinite Automation Systems, Inc. on September 26, 2019. The closing of the transaction is subject to a number of conditions precedent, including satisfactory due diligence and the execution of definitive agreements, including employment agreements with the principal officers and directors of Infinite Automation Systems.お知らせ • Sep 26IIOT-OXYS, Inc. announced that it expects to receive $0.5 million in funding from Catalytic Capital, LLC and another investorIIOT-OXYS, Inc. (OTCPK:ITOX) announced that it has entered into a securities purchased agreement for the private placement of 12% senior secured convertible notes for gross proceeds of $500,000 on March 6, 2019. The note is convertible, in whole or in part, into common shares at a conversion price of $0.20 per share. The note bears interest at a rate of 12% per annum payable quarterly. The will note matures on March 1, 2021. The notes will be issued in 3 tranches of $100,000 and last tranche of $200,000. The company will issue warrants to purchase one share of the company for 50% of the number of shares of shares issuable upon conversion of the note. Each warrant is immediately exercisable at $0.30 per share and expires five years from the issuance date. The notes will be issued pursuant to exemption provided under Regulation D. On the same date, the company has received $100,000 from Catalytic Capital, LLC and YVSGRAMORAH LLC for $50,000 each in its first tranche. The company also issued 250,000 warrants in the tranche.お知らせ • Aug 18IIOT-OXYS, Inc. announced delayed 10-Q filingOn 08/17/2020, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 30IIOT-OXYS, Inc. announced delayed 10-Q filingOn 06/29/2020, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.決済の安定と成長配当データの取得安定した配当: ITOXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: ITOXの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場IIOT-OXYS 配当利回り対市場ITOX 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ITOX)n/a市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Software)0.9%アナリスト予想 (ITOX) (最長3年)n/a注目すべき配当: ITOXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: ITOXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: ITOXの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: ITOXが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/16 03:00終値2026/05/14 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋IIOT-OXYS, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 01IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2026, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 11/14/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 08/14/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16IIOT-OXYS, Inc. announced delayed 10-Q filingOn 05/15/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 22IIOT-OXYS, Inc. announced that it expects to receive $0.21 million in funding from GHS Investments, LLCIIOT-OXYS, Inc. entered into a Securities Purchase Agreement with returning investor GHS Investments, LLC in the amount of up to $210,000 on MArch 21, 2025. The SPA provides for GHS’s purchase, from time to time, of up to 210 shares of the Company’s newly-designated Series D Convertible Preferred Stock (the “ Preferred Stock ”). The initial closing under the SPA consisted of 60 shares of Preferred Stock, stated value $1,200 per share, issued to GHS for an initial purchase price of $60,000, or $1,000 per share. At GHS and the Company’s option, and subject to the terms of the SPA and the Certificate of Designation for the Preferred Stock (the “ COD ”), additional closings in the aggregate amount of up to 150 shares of Preferred Stock for a total aggregate purchase price of up to $150,000 may take place.
お知らせ • Nov 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 11/14/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 08/14/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18IIOT-OXYS, Inc. announced delayed 10-Q filingOn 05/16/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 04/01/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jun 16IIOT-OXYS, Inc. Appoints William D'Agostino to its Advisory BoardIIOT-OXYS, Inc. announced the appointment of William D'Agostino to its Advisory Board as a Technical Sales Consultant for his expertise in Biotechnology and Pharmaceutical Continuous Manufacturing Processes.
お知らせ • May 16IIOT-OXYS, Inc. announced delayed 10-Q filingOn 05/15/2023, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 01IIOT-OXYS, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 , First Quarter and Full Year of 2023IIOT-OXYS, Inc. provided revenue guidance for the fourth quarter and full year ended December 31, 2022, first quarter and full year of 2023. As predicted, the fourth quarter revenue exceeded that in the third quarter. Overall, 2022 annual revenue exceeded that of 2020 and 2021 combined.This first quarter of 2023 is already on track to exceed the fourth quarter revenue in 2022. Overall, The company expects 2023 revenue to exceed that in 2022.
お知らせ • Dec 06IIOT-OXYS, Inc. announced that it has received $0.061 million in fundingOn December 5, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. J.H. Darbie & Co., Inc. acted as a finder in the transaction. The company has paid $1,220 as finder fee in the transaction.
お知らせ • Nov 25IIOT-OXYS, Inc. Provides Revenue Guidance for the Second Half and Full Year 2022IIOT-OXYS, Inc. provided revenue guidance for the second half and full year 2022. The company expected revenue for the second half of 2022 will exceed that generated in the first half of 2022.In total, the company expected that total revenue for 2022 will be approaching 2019 levels.
お知らせ • Jul 13IIOT-OXYS, Inc. announced that it has received $0.027273 million in fundingOn July 12, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. The company has paid $546 to the finder J.H. Darbie & Co.
お知らせ • Jun 24IIOT-OXYS, Inc. announced that it has received $0.030144 million in fundingOn June 23, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. The company has paid $603 to the finder J.H. Darbie & Co.
お知らせ • Jun 09+ 2 more updatesIIOT-OXYS, Inc. Announces CFO ChangesIIOT-OXYS, Inc. announced that on June 2, 2022, Clifford L. Emmons resigned as Interim Chief Financial Officer and, on the same date, Karen McNemar, age 53, was appointed as the Interim Chief Financial Officer (Principal Financial and Accounting Officer) of the Company. Except as mentioned herein, there are no other arrangements or understandings between Ms. McNemar and any other persons pursuant to which Ms. McNemar was selected in the officer position above. There are no family relationships between Ms. McNemar and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer. Ms. McNemar has served as Chief Operating Officer since September 20, 2018. From 1998 until August 2017, Ms. McNemar served in many capacities for Medtronic which included as a Senior Director of R&D Operations. Ms. McNemar is a collaborative strategic global business leader with extensive experience in New Product Development and Operations, building strong and effective diverse teams across organizations at all levels. Ms. McNemar is also a trusted advisor, recognized for successful process and program management, with a focus on leading complex initiatives and analyzing data and processes to identify solutions to increase organizational productivity and performance. Ms. McNemar received her Bachelor of Science in Industrial Engineering and Operations Research.
お知らせ • May 24IIOT-OXYS, Inc. announced that it has received $0.043096 million in fundingOn May 23, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. The company has paid $4,310 to the finder J.H. Darbie & Co.
お知らせ • Apr 01IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2022, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 26IIOT-OXYS, Inc. announced that it has received $0.051 million in fundingOn February 24, 2022, IIOT-OXYS, Inc. closed the transaction. The company has received funding from one investor.
お知らせ • Apr 02IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2021, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 18IIOT-OXYS, Inc. Appoints Chandran Seshagiri as Company's Advisory Board ChairmanIIOT-OXYS, Inc. announced the appointment of Chandran Seshagiri as the company's Advisory Board Chairman. Chandran is uniquely qualified to lead company Advisory Board, as he has made significant contributions to company past successful projects and continues to lead company algorithm development efforts on current and future projects. His passion for transforming complex signals into actionable information began with his work at the Harvard-MIT Division of Health Sciences and Technology, where he completed his Ph.D. Chandran's work analyzing physiological time series signals to enable personalized delivery of anesthesia as well as neurostimulation therapy has translated well to the time series data and predictive analyses required for Smart Manufacturing and Structural Health Monitoring applications for IIOT-OXYS, Inc.'s customers.
お知らせ • Sep 28IIOT-OXYS, Inc. (OTCPK:ITOX) entered into a letter of intent to acquire Infinite Automation Systems, Inc.IIOT-OXYS, Inc. (OTCPK:ITOX) entered into a letter of intent to acquire Infinite Automation Systems, Inc. on September 26, 2019. The closing of the transaction is subject to a number of conditions precedent, including satisfactory due diligence and the execution of definitive agreements, including employment agreements with the principal officers and directors of Infinite Automation Systems.
お知らせ • Sep 26IIOT-OXYS, Inc. announced that it expects to receive $0.5 million in funding from Catalytic Capital, LLC and another investorIIOT-OXYS, Inc. (OTCPK:ITOX) announced that it has entered into a securities purchased agreement for the private placement of 12% senior secured convertible notes for gross proceeds of $500,000 on March 6, 2019. The note is convertible, in whole or in part, into common shares at a conversion price of $0.20 per share. The note bears interest at a rate of 12% per annum payable quarterly. The will note matures on March 1, 2021. The notes will be issued in 3 tranches of $100,000 and last tranche of $200,000. The company will issue warrants to purchase one share of the company for 50% of the number of shares of shares issuable upon conversion of the note. Each warrant is immediately exercisable at $0.30 per share and expires five years from the issuance date. The notes will be issued pursuant to exemption provided under Regulation D. On the same date, the company has received $100,000 from Catalytic Capital, LLC and YVSGRAMORAH LLC for $50,000 each in its first tranche. The company also issued 250,000 warrants in the tranche.
お知らせ • Aug 18IIOT-OXYS, Inc. announced delayed 10-Q filingOn 08/17/2020, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 30IIOT-OXYS, Inc. announced delayed 10-Q filingOn 06/29/2020, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.